3 results on atopic dermatitis
Primary objectiveTo evaluate if tralokinumab after 14 weeks of treatment (at steady state) changes the metabolism of substrates of CYP 1A2, 2C9, 2C19, 2D6, or 3A4 pathways in subjects with moderate-tosevere atopic dermatitisSecondary objectivesTo…
PrimaryPart 3 - Repeated doses in atopic dermatitis (AD) patients - PDY16891* To evaluate the safety and tolerability of SAR443726 after repeated SC doses in adult participants with moderate-to-severe ADSecondaryPart 3 - Repeated doses in AD…
Primary Objective: To assess the anti-neoplastic activity of flotetuzumab in patients with PIF/ER AML, as determined by the proportion of patients who achieve CR/CRhSecondary Objectives:To describe response rate, duration of response, event-free…